Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-03-06
1997-05-13
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142262, 514280, 514282, 514304, 514315, 514646, A61K 3155, A61K 3154, A61K 3144, A61K 31135
Patent
active
056293070
ABSTRACT:
This invention discloses that ibogaine, a plant derivative, can be used as a safe NMDA antagonist at relatively high dosages (including dosages high enough to cause hallucinations), to reduce or prevent excitotoxic brain damage due to stroke, cardiac arrest, trauma or other forms of neuronal injury or degeneration, without causing the neurotoxic side effects caused by other NMDA antagonist drugs. The relative safety of ibogaine is due to antagonist activity at neuronal sigma receptors, which had not been known prior to discovery by the Applicant. This invention also discloses that ibogaine also can be administered in combination with (1) drugs that suppress activity at muscarinic acetylcholine receptors, or (2) drugs which suppress activity at the kainic acid subclass of glutamate receptors, to reduce or avoid the hallucinatory effects of ibogaine and provide a higher level of neuroprotective activity.
REFERENCES:
patent: 4499096 (1985-02-01), Lotsof
patent: 4587243 (1986-05-01), Lotsof
patent: 4857523 (1989-08-01), Lotsof
patent: 5026697 (1991-06-01), Lotsof
patent: 5034400 (1991-07-01), Olney
patent: 5152994 (1992-10-01), Lotsof
Deecher, D.C., et al, "Mechanisms of action of ibogaine and harmaline congeners based on radioligand studies," Brain Res. 571: 242-247 (1992).
Glick, S.D., et al, "Effects and aftereffects of ibogaine on morphine self-administration in rats," Eur. J. Pharmacol. 195:341-435 (1991).
Glick, S.D., et al, "Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum," Brain Res. 628:201-208 (1993).
Popik, P., et al, "The putative anti-addictive drug ibogaine is a competitive inhibitor of[.sup.3 H]Mk-801 binding to the NMDA receptor complex,"Psychopharmacology 114:672-674 (1994).
Sershen, H., et al, "Ibogaine antagonizes cocaine-induced locomotor stimulation in mice," Life Sci 50:1079-86 (1992).
Sershen, H., et al, "Ibogaine reduces preference for cocaine consumption in C57BL/6By mice," Pharmacol Biochem Behav 47:13-19 (1994).
Green et al., "Antinociception opioids and the cholinergic System; Prog. Neurobiol.", (1986) 26/2 (119-146) see abstract.
Kelly Patrick D.
Weddington Kevin E.
LandOfFree
Use of ibogaine in reducing excitotoxic brain damage does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of ibogaine in reducing excitotoxic brain damage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ibogaine in reducing excitotoxic brain damage will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1385523